We and other research groups have previously described that levels of the anabolic hormone dehydroepiandrosterone sulfate (DHEA-S) are lowered in individuals who report prolonged stress. We have also shown that the DHEA-S production capacity during acute stress is attenuated in individuals reporting high prolonged stress. This study aimed to further investigate the DHEA and DHEA-S production capacity in relation to prolonged stress. Eighty-one healthy participants in the age 20-50 years old were included in the study and divided into a low stress (n = 45) and a high stress group (n = 36) according their response to a single question regarding perceived stress during the preceding month.
They underwent the Trier Social Stress Test while blood samples were drawn before, during and after the stress test. The concentration of DHEA, DHEA-S, cortisol and ACTH was measured. The results showed that the high stress group exhibited a significantly lower response of DHEA-S (40% lower) than the low stress group, while DHEA, cortisol and ACTH responses did not differ between the groups. Reduced DHEA-S production may constitute one of the links between stress and poor health.
Inter-individual differences in pain anticipation and pain perception in migraine: Neural correlates of migraine frequency and cortisol-to-dehydroepiandrosterone sulfate (DHEA–S) ratio
Previous studies targeting inter-individual differences in pain processing in migraine mainly focused on the perception of pain. Our main aim was to disentangle pain anticipation and perception using a classical fear conditioning task, and investigate how migraine frequency and pre-scan cortisol-to-dehydroepiandrosterone sulfate (DHEA-S) ratio as an index of neurobiological stress response would relate to neural activation in these two phases. Functional Magnetic Resonance Imaging (fMRI) data of 23 participants (18 females; mean age: 27.61± 5.36) with episodic migraine without aura were analysed.
We found that migraine frequency was significantly associated with pain anticipation in brain regions comprising the midcingulate and caudate, whereas pre-scan cortisol-to DHEA-S ratio was related to pain perception in the pre-supplementary motor area (pre-SMA). Both results suggest exaggerated preparatory responses to pain or more general to stressors, which may contribute to the allostatic load caused by stressors and migraine attacks on the brain.
Circulating DHEA–S levels and major cardiovascular outcomes in chronic Chagas cardiomyopathy: A prospective cohort study
Objective: To analyze the association of circulating dehydroepiandrosterone sulfate (DHEA-S) levels with cardiovascular outcomes in patients with chronic Chagas cardiomyopathy (CCM) diagnosis.
Background: DHEA-S is among the main endogenous steroid hormones. Some studies have suggested a relevant role of this hormone in infections and the setting of CCM. Nevertheless, no study has evaluated the prognostic role of DHEA-S in CCM patients.
Methods: Prospective cohort study. Patients with CCM and reduced ejection fraction were included. We explored the association of DHEA-S levels with NT-proBNP levels and echocardiographic variables using linear regression models. Next, by using Cox Proportional Hazard models, we examined whether levels of DHEA-S could predict a composite outcome (CO) including all-cause mortality, cardiac transplantation, and implantation of a left ventricular assist device (LVAD).
Results: Seventy-four patients were included (59% males, median age: 64 years). After adjustment for confounding factors, high DHEA-S levels were associated with better LVEF, lower left atrium volume, end-systolic volume of the left ventricle and lower NT-proBNP levels. 43% of patients experienced the CO during a median follow-up of 40 months. Increased levels of DHEA-S were associated with a lower risk of developing the CO (HR 0.43; 95%CI 0.21-0.86). Finally, adding DHEA-S to the multivariate model did not improve the prediction of the CO, but substituting NT-proBNP in the model with DHEA-S showed similar performance.
Conclusions: In patients with CCM, higher DHEA-S levels were associated with lower mortality, heart transplantation, and LVAD implantation. Further larger studies are required to confirm our results and assess causality.
Comparative Profiling of Salivary Cortisol and Salivary DHEA–S Among Healthy Pregnant and Non-Pregnant Women
- During pregnancy, circulatory cortisol levels increase, remaining steady over the second-third trimester. In contrast, profile of salivary cortisol during pregnancy is debatable, more influenced by factors like time of sample collection in the day. Circulatory DHEA-S decrease by at least 50% over the second-third trimester of pregnancy. However, profile of salivary DHEA-S is unclear. Objective was to determine changes in salivary cortisol and DHEA-S in healthy pregnant women, compared to non-pregnant women during late morning-early afternoon sampling to avoid fluctuations associated with other times.
- Pregnant women in their second-third trimester prospectively (n=500) and non-pregnant women (n=133) were enrolled in study with informed consent. Live birth outcome with no pregnancy complications and≥2.5 Kg infant birth weight were included. Concentrations of salivary cortisol and DHEA-S were determined through ELISA assays. Compared to non-pregnant women, pregnant women demonstrated significant increases in salivary cortisol [median (interquartile range)=4.2 (5.1) nmol/l vs. 17.2 (13.9) nmol/l, p<0.001] and salivary DHEA-S median (interquartile range)=2.7 (2.9) nmol/l vs. 3.8 (3.2) nmol/l, p<0.001).
- Consistently, quartile scores representing higher levels of salivary cortisol and DHEA-S concentrations demonstrated significant association with pregnancy. Quartile scores representing higher salivary cortisol/DHEA-S ratio demonstrated significant association with pregnancy. Study suggests the indicated time range of saliva sampling might best parallel the established profile of circulatory cortisol in pregnant women. However, unlike cortisol, study indicates that the salivary DHEA-S profile is distinct from the well-known profile of circulatory DHEA-S during pregnancy. A combinatorial approach involving both salivary and circulatory compartments could provide comprehensive picture of DHEA-S and hypothalamus-pituitary-adrenal axis during pregnancy.
DHEA-S |
|||
DE1562 | Demeditec Diagnostics | 96 | 95 EUR |
DHEA-S |
|||
GWB-C990DB | GenWay Biotech | 1x96 Assays | Ask for price |
DHEA-S |
|||
GWB-DF2891 | GenWay Biotech | 1x96 Assays | Ask for price |
DHEA-S |
|||
MBS340681-01mg | MyBiosource | 0.1mg | 1050 EUR |
DHEA-S |
|||
MBS340681-1mg | MyBiosource | 1mg | 3920 EUR |
DHEA-S |
|||
MBS340681-5x1mg | MyBiosource | 5x1mg | 17460 EUR |
DHEA-S ELISA |
|||
E22-HC9024 | EnoGene | 96T | 495 EUR |
DHEA-S ELISA |
|||
GWB-BQK1B7 | GenWay Biotech | 96 Well Plate | Ask for price |
DHEA-S ELISA |
|||
MBS8579258-5x96Tests | MyBiosource | 5x96Tests | 2735 EUR |
DHEA-S ELISA |
|||
MBS8579258-96Tests | MyBiosource | 96Tests | 595 EUR |
DHEA-S Antibody |
|||
GWB-F09C57 | GenWay Biotech | 0.1 ml | Ask for price |
DHEA-S ELISA Kit |
|||
MBS580010-5x96StripWells | MyBiosource | 5x96-Strip-Wells | 1320 EUR |
DHEA-S ELISA Kit |
|||
MBS580010-96StripWells | MyBiosource | 96-Strip-Wells | 330 EUR |
DHEA-S ELISA Kit |
|||
MBS580169-5x96StripWells | MyBiosource | 5x96-Strip-Wells | 1320 EUR |
DHEA-S ELISA Kit |
|||
MBS580169-96StripWells | MyBiosource | 96-Strip-Wells | 305 EUR |
DHEA-S ELISA Kit |
|||
MBS495539-5x96Tests | MyBiosource | 5x96Tests | 1555 EUR |
DHEA-S ELISA Kit |
|||
MBS495539-96Tests | MyBiosource | 96Tests | 340 EUR |
DHEA-S Standard, 350UL |
|||
C201-350UL | Arbor Assays | 350UL | 207 EUR |
DHEA-S Standard, 70UL |
|||
C201-70UL | Arbor Assays | 70UL | 85 EUR |
Rat DHEA-S ELISA Kit |
|||
EF017685 | Nova Lifetech | 96tests | 566 EUR |
Human DHEA-S ELISA KIT |
|||
EF006758 | Nova Lifetech | 96tests | 566 EUR |
Mouse DHEA-S ELISA Kit |
|||
EF013566 | Nova Lifetech | 96tests | 566 EUR |
DHEA-S (human) ELISA Kit |
|||
K7428-100 | Biovision | each | 940.8 EUR |
RealScreen DHEA-S ELISA Kit |
|||
EL102-096 | GenDepot | 96T | 1161.6 EUR |
DHEA-S ELISA Kit (1 Plate) |
|||
K054-H1 | Arbor Assays | 1x96 well plate | 444 EUR |
DHEA-S ELISA Kit (5 Plate) |
|||
K054-H5 | Arbor Assays | 5x96 well plate | 1775 EUR |
Anti-Dehydroepiandrosterone Sulphate (DHEA-S) |
|||
MBS340106-10mg | MyBiosource | 10mg | 1920 EUR |
Anti-Dehydroepiandrosterone Sulphate (DHEA-S) |
|||
MBS340106-1mg | MyBiosource | 1mg | 615 EUR |
Anti-Dehydroepiandrosterone Sulphate (DHEA-S) |
|||
MBS340106-5x10mg | MyBiosource | 5x10mg | 8470 EUR |
Dehydroepiandrosterone Sulfate (DHEA-S) Antibody |
|||
abx342013-100g | Abbexa | 100 µg | Ask for price |
Comparative profiling of prenatal cortisol and DHEA–S among pregnant women with poor birth outcome and pregnant women with normal birth outcome
Context: Cortisol and dehydroepiandrosterone-sulfate (DHEA-S) are indispensable hormones for normal pregnancy. It is unclear if these hormones, specifically DHEA-S can offer value for predicting poor birth outcome.
Objective: To compare prenatal cortisol and DHEA-S levels among pregnant women with normal or poor birth outcome.
Design-patients: Plasma and saliva were collected prospectively from women in second-third trimester of pregnancy. Women with normal birth outcome (NBO), (n=501) included live birth, no pregnancy complications and ≥ 2.5Kg infant birth weight. Women with poor birth outcome included adverse birth (ABO), (n=50) or low birth weight outcome (LBW), (n=147).
Measurements: ELISA was performed to measure hormone concentrations in plasma and saliva.
Results: Circulatory-DHEA-S levels in pregnant women with ABO were higher than women with NBO (p=0.043). Among ABO, only stillbirth cases demonstrated significant increase in circulatory-DHEA-S levels (p=0.006). Circulatory and salivary cortisol/DHEA-S ratio was lower among women with stillbirth (p=0.004) and ABO outcome (p=0.043) respectively compared to women with NBO. Consistently, increased odds of ABO were observed in pregnant women with highest circulatory-DHEA-S levels (odds ratio quartile score 1 vs 4, 2.79, p=0.027) and lowest salivary cortisol/DHEA-S ratio (score 4 vs 2, 2.83, p=0.025). Increased odds of stillbirth outcome were observed in pregnant women with highest circulatory-DHEA-S levels (odds ratio quartile score 1 vs 4, 8.47, p=0.046) and lowest circulatory cortisol/DHEA-S ratio (score 4 vs 1, 4.803, p=0.048). Associations remained significant after adjusting for confounders. Women with LBW did not demonstrate significant changes in cortisol or DHEA-S levels.
Conclusion: Prenatal measurement of DHEA-S or cortisol/DHEA-S ratio may offer significant value for predicting adverse birth, specifically stillbirth outcome.